Effects of rosiglitazone on aortic expressions of PPAR-γ, α-SMA, and SM22α using Western blot analysis. The SHR aortas exhibited reduced PPAR-γ (A), α-SMA (B), and SM22α (C) expression levels compared with WKY aortas. Rosiglitazone treatment improved the expression of PPAR-γ (A), α-SMA (B), and SM22α (C) both in SHR and WKY aortas. Data are presented as mean ± S.E. (n = 6). *, p < 0.05 versus WKY-veh; #, p < 0.05 versus SHR-veh. veh, treated with vehicle; rsg, treated with rosiglitazone.